327 related articles for article (PubMed ID: 25683938)
1. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Kan X; Jing Y; Wan QY; Pan JC; Han M; Yang Y; Zhu M; Wang Q; Liu KH
Eur Rev Med Pharmacol Sci; 2015; 19(2):247-55. PubMed ID: 25683938
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
[TBL] [Abstract][Full Text] [Related]
3. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
5. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
Zhu K; Huang J; Lai L; Huang W; Cai M; Zhou J; Guo Y; Chen J
Radiology; 2018 Jul; 288(1):300-307. PubMed ID: 29688153
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
Giorgio A; Merola MG; Montesarchio L; Merola F; Santoro B; Coppola C; Gatti P; Amendola F; DI Sarno A; Calvanese A; Matteucci P; Giorgio V
Anticancer Res; 2016 Nov; 36(11):6179-6183. PubMed ID: 27793949
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Fukuda H; Numata K; Moriya S; Shimoyama Y; Ishii T; Nozaki A; Kondo M; Morimoto M; Maeda S; Sakamaki K; Morita S; Tanaka K
Radiology; 2014 Aug; 272(2):598-604. PubMed ID: 24689883
[TBL] [Abstract][Full Text] [Related]
8. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
Park JG; Park SY; Lee HW
World J Gastroenterol; 2015 Feb; 21(8):2568-72. PubMed ID: 25741170
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
11. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
[TBL] [Abstract][Full Text] [Related]
12. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
13. Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
Liang HY; Lu LG; Hu BS; Li Y; Shao PJ
Chin Med J (Engl); 2013 Nov; 126(22):4270-6. PubMed ID: 24238511
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
15. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib combined with radiofrequency ablation in the treatment of a patient with renal cell carcinoma plus primary hepatocellular carcinoma.
Gang G; Hongkai Y; Xu Z
J Cancer Res Ther; 2015; 11(4):1026. PubMed ID: 26881596
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
Li Y; Zheng YB; Zhao W; Liu B; Hu BS; He X; Huang JW; Lu LG
Med Oncol; 2013 Dec; 30(4):730. PubMed ID: 24048774
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Park JG
Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
